Clinical Pharmacology and Pharmacy, 2015 (vol. 29), issue 3
Editorial
Slovo úvodem
doc. MUDr. Karel Urbánek, Ph.D.
Klin Farmakol Farm. 2015;29(3) 
Main topic
Slovo úvodem
doc. MUDr. Jaromír Bystroň, CSc.
Klin Farmakol Farm. 2015;29(3):93-94
What are the current options for affecting immunity in routine clinical practice?
Jaromír Bystroň
Klin Farmakol Farm. 2015;29(3):95-99
The author presents an overview of the current options of immunomodulatory therapy in routine clinical practice. They are divided into products that are used primarily for anti-inflammatory therapy, immunosubstitution and immunostimulation. Also addressed is the current status of OTC products for „stimulation of immunity“ from the perspective of evidence-based medicine.
Modern antihistamines in treating allergies: current trends in symptomatic therapy of allergic conditions
Jaroslava Braunová, Mojmír Račanský
Klin Farmakol Farm. 2015;29(3):100-104
Allergic diseases are a serious problem in modern medicine. It is not only a question of pollinosis, but also of other allergic diseases such as bronchial asthma, atopic dermatitis, urticaria, angioedema or anaphylactic reaction. Antihistamines play one of the major roles in the treatment of these conditions.
Inhaled corticosteroids in treating bronchial asthma: are we supposed to be afraid of them or be grateful for their effect?
Beáta Hutyrová
Klin Farmakol Farm. 2015;29(3):105-107
Inhaled corticosteroids (ICSs) are the first-choice therapy of persistent bronchial asthma. Their widespread use has led to a significant reduction in the morbidity and mortality of asthma patients. Local side effects are well known and relatively frequent. Conflicting data have been reported regarding systemic side effects of ICSs that are frequently forgotten in clinical practice. Side effects of ICSs and their benefits in the therapy of bronchial asthma are discussed in this paper.
The biologically active phospholipids isolated from egg yolk increasing cytotoxic effect of temozolomide
Jozef Hatok, Eva Blahovcová, Henrieta ©kovierová, Radovan Murín
Klin Farmakol Farm. 2015;29(3):108-112
on human glioblastoma cells Extracts of biologically active phospholipids (BAP) may exert a positive effect on inhibition of tumor growth and may be used as additive compounds to supplement palliative tumor treatment. The exact mechanisms by which BAP affect the cancer cells are still unknown. Among brain tumors, glioblastoma multiforme (GBM) is considered the most aggressive and the most common primary brain tumor in adults. The treatment of GBM includes surgery, radiotherapy and chemotherapy with an alkylating agent temozolomide (TMZ). With the aim to study the survival of human glioblastoma cells, in media supplemented with BAP alone or...
Review articles
Clinical utilization of probiotics in preventing and treating gastrointestinal disorders
Iveta Ondriová, Terézia Fertaµová, Dagmar Magurová
Klin Farmakol Farm. 2015;29(3):116-118
Abstract: Probiotics are live microorganisms which, when administered in sufficient quantities, have a proven beneficial effect on the host. Their basic characteristic is adhesion to cells of the intestinal mucosa, thereby displacing pathogens. At the same time, due to the contact of probiotic bacteria with the cells of the gut-associated lymphoid tissue (GALT), activation of multiple mechanisms of immunity occurs. Typical goals of probiotic therapy include infectious and acute viral diarrhea as well as diarrhea after irradiation, inflammatory bowel diseases, Helicobacter pylori infection, and the prevention of allergies and atopic dermatitis.
Dimethyl fumarate in treating relapsing-remitting multiple sclerosis
Eva Meluzínová, Martin Bortlík
Klin Farmakol Farm. 2015;29(3):119-122
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS). With early initiation of treatment, it is possible to slow down the whole immunopathological process. Treatment is initiated with first-line drugs optimally after the first symptom of disease. Patients in whom the effect of this therapy is inadequate require escalation to second-line drugs. In February 2014, dimethyl fumarate (DMF) was registered for the treatment of relapsing-remitting MS (RR-MS) in the Czech Republic. It is an oral medication that meets the criterion of efficacy while having good tolerance, safety, and the...
ABP501, SB5.
Hana Ciferská, Monika Urbanová
Klin Farmakol Farm. 2015;29(3):124-128
Biosimilars in treating inflammatory rheumatic diseases The advent of biological therapy has significantly positively influenced the prognosis and quality of life of patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). The administration of biologic drugs results in suppressing disease activity, affecting x-ray progression, and improving the mobility and quality of life of the patient. The benefit of this treatment largely exceeds the possible risks associated with its administration. Biological therapy is associated with high costs that, to a certain degree, can be reduced by using biosimilar drugs, or biosimilars. Biosimilars...
Peritoneal dialysis
Vladimíra Bednářová
Klin Farmakol Farm. 2015;29(3):129-132
Peritoneal dialysis is one of the treatment options for chronic kidney failure. It is the first-choice method of treatment in patients indicated for deceased-donor kidney transplantation. The principle of this method consists in removing substances and water through the peritoneum into the dialysis fluid filled into the abdominal cavity. Peritoneal dialysis is self-administered by the patient at home and there are monthly follow-up visits at the dialysis centre. The dialysis fluid is introduced and removed from the abdominal cavity manually (the CAPD method) or by using a device (the APD method). A peritoneal catheter is placed permanently...
Information
7. česko-slovenská konference Klinické farmakologie - Olomouc 11.-12. září 2015
Rostislav Večeřa
Klin Farmakol Farm. 2015;29(3):133
Ohlédnutí za letoąními mezinárodními kongresy klinické farmakologie
Jan Strojil
Klin Farmakol Farm. 2015;29(3):134-135
Company information
Proč inzulinový analog lispro v koncentraci 200 U/ml?
Denisa Janíčková ®ďárská, Milan Kvapil
Klin Farmakol Farm. 2015;29(3):113-114